News headlines about Spero Therapeutics (NASDAQ:SPRO) have trended somewhat negative on Saturday, Accern reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spero Therapeutics earned a news impact score of -0.04 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.7343366488142 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
A number of equities analysts have recently weighed in on SPRO shares. Bank of America assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They set a “neutral” rating on the stock. Oppenheimer assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They set a “buy” rating and a $30.00 price objective on the stock. Stifel Nicolaus assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Cowen assumed coverage on Spero Therapeutics in a research note on Monday, November 27th. They set an “outperform” rating on the stock.
Spero Therapeutics (SPRO) traded down $0.10 during trading on Friday, reaching $12.25. The company’s stock had a trading volume of 18,900 shares, compared to its average volume of 71,313. The company has a market cap of $176.02 and a price-to-earnings ratio of -4.30. Spero Therapeutics has a 12-month low of $9.84 and a 12-month high of $15.40.
Spero Therapeutics (NASDAQ:SPRO) last issued its earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.43) by ($33.59). The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.20 million. equities analysts anticipate that Spero Therapeutics will post -8.52 earnings per share for the current year.
In other Spero Therapeutics news, Director Casper Breum bought 214,285 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The shares were purchased at an average price of $14.00 per share, with a total value of $2,999,990.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 649,356 shares of company stock worth $9,090,984. Company insiders own 13.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Negative News Coverage Somewhat Unlikely to Impact Spero Therapeutics (SPRO) Stock Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/14/spero-therapeutics-spro-given-coverage-optimism-rating-of-0-04.html.
About Spero Therapeutics
SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.